A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21. [electronic resource]
Producer: 20080807Description: 590-8 p. digitalISSN:- 1556-1380
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Dose-Response Relationship, Drug
- ErbB Receptors -- antagonists & inhibitors
- Erlotinib Hydrochloride
- Female
- Follow-Up Studies
- Humans
- Lung Neoplasms -- drug therapy
- Male
- Middle Aged
- Neoplasm Staging
- Ontario -- epidemiology
- Prognosis
- Proportional Hazards Models
- Protein Kinase Inhibitors -- administration & dosage
- Quinazolines -- administration & dosage
- Survival Rate
- Time Factors
No physical items for this record
Publication Type: Comparative Study; Journal Article; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.